Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glutsch

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Oncogene|December 2, 2020
Correction: The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expressionChristina Jessen, Julia K C Kreß, Apoorva Baluapuri, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesAnne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Oncogene|December 2, 2020
Correction: The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expressionChristina Jessen, Julia K C Kreß, Apoorva Baluapuri, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinomaViola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesAnne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Pageof 5